Interventional News’ top 10 most popular stories for May 2021


top 10Two of our top stories this month come from the International Symposium on Endovascular Therapy (ISET; 9–11 May, Miami, USA), which returned as an in-person meeting in 2021: the live and online audiences heard a run-down of new tools on the horizon for the treatment of chronic limb-threatening ischaemia (CLTI), and the Auryon atherectomy system showcased at the conference offered “a new look at laser”. A commentary from Gerard S Goh (Melbourne, Australia) and Markus P Schlaich (Perth, Australia) explored the potential of multi-organ denervation, and, in terms of vascular access coverage, readers were offered insight into a new wearable device for AV fistula remote monitoring that shows promise, but is facing commercial challenges. top 10

1. New tools on the horizon for CLTI patients revealed at ISET 2021

“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider (University of California San Francisco, San Francisco, USA) told delegates attending the International Symposium on Endovascular Therapy (ISET; 9–11 May, Miami, USA), in a talk focusing on innovative tools on the horizon for the treatment of chronic limb-threatening ischaemia (CLTI). “I think critical limb ischaemia has come to the forefront of our practices and of community awareness, and finally now the tools are starting to show that,” he opined.

2. Multi-organ denervation to combat cardiometabolic disease: A novel concept put to the test

Following a successful proof-of-concept study, Gerard S Goh and Markus P Schlaich have embarked upon a first-in-human study to explore the safety and efficacy of combined renal and common hepatic artery denervation in patients with type 2 diabetes and hypertension. Here, the co-principal investigators describe the rationale behind their single blinded, multi-centre, prospective feasibility study—named the MODUS trial—and explore the “pandemic” of cardiometabolic disease.

3. Wearable device for AV fistula remote monitoring shows promise—but faces commercial challenges

A new wearable device designed to remotely monitor arteriovenous (AV) fistulae function in dialysis access patients uncovered promising data leading one set of researchers to conclude the technology offers hope for improved care and lower costs among a challenging patient population.

4. More mixed results for DCBs in AV access maintenance as evidence mounts

Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with uncertainty. However, specific modelling suggests fewer reinterventions could reinforce economic benefits when the IN.PACT AV device (Medtronic) is used, and sirolimus presents new directions, experts say.

5. “A new look at laser”: Positive initial data presented at ISET for the Auryon atherectomy system

The Auryon atherectomy system (AngioDynamics) “represents an exciting new technology”, John Rundback (Advanced Interventional and Vascular Services, LLP, Teaneck, USA) opined at the International Symposium on Endovascular Therapies (ISET; 9–11 May, Miami, USA, and online), speaking on behalf of the Pathfinder I registry investigators. “I think it has really got a lot of traction; we found it a very useful tool across a wide range of plaque morphologies and vessel beds. Further iterations of this platform will hopefully improve its performance further.”

6. SRFA allows IRs to predict ablation success intraprocedurally

Volumetric assessment of the periablational safety margin can be used as an intraprocedural tool to evaluate local treatment success in patients with colorectal liver metastases referred to stereotactic radiofrequency ablation (SRFA), a recent study in European Radiology concludes. This could replace the visual, side-by-side evaluation of periablational safety margins, the investigators suggest, which is “challenging, even for experienced radiologists”. Authored by Gregor Laimer, Reto Bale (both Medical University Innsbruck, Innsbruck, Austria) and colleagues from Dresden (Germany), Milan (Italy), Jerusalem (Israel), and Boston (USA), the report offers an objective tool that enables the immediate, real-time determination of the extent and percentage of the safety margin requiring ablation, enabling the reliable prediction of procedural outcome success.

7. iVascular receives CE mark for iCover covered stent

iVascular has received CE mark approval for its balloon-expandable covered stent, iCover, a press release from the company states.

8. Micro Medical Solutions receives FDA breakthrough device designation for MicroStent vascular stent

Micro Medical Solutions (MMS) announced this month that the US Food and Drug Administration (FDA) has granted breakthrough device designation for its MicroStent vascular stent. This novel technology is designed to achieve and maintain vessel patency, enhance wound treatment, and improve quality of life and blood flow in order to reduce amputation and mortality for patients with chronic limb-threatening ischaemia (CLTI) resulting from peripheral arterial disease (PAD).

9. Bifurcated T-stent reconstruction is safe and effective treatment for HVOO in orthotopic liver transplant patients

A study has found that bifurcated T-stent reconstruction offers a safe and effective treatment option for hepatic venous outflow obstruction (HVOO) with anastomotic stenoses in orthotopic liver transplantation (OLT) recipients.

10. XO Score scoring sheath platform earns CE mark approval

Transit Scientific recently announced it has received CE mark clearance in the European Union for the XO Score scoring sheath platform to facilitate dilation of stenotic material in the peripheral vasculature including popliteal, infrapopliteal, and native or synthetic arteriovenous dialysis fistulae. top 10 top 10


Please enter your comment!
Please enter your name here